600351 亚宝药业
已收盘 12-31 15:00:00
资讯
新帖
简况
亚宝药业（广东横琴）有限公司成立
证券日报 · 2025-12-28
亚宝药业（广东横琴）有限公司成立
每周股票复盘：亚宝药业（600351）拟每10股派现2元
证券之星 · 2025-12-28
每周股票复盘：亚宝药业（600351）拟每10股派现2元
亚宝药业（600351）披露拟每10股派发现金红利2元，12月24日股价上涨0.15%
证券之星 · 2025-12-24
亚宝药业（600351）披露拟每10股派发现金红利2元，12月24日股价上涨0.15%
亚宝药业（600351）披露拟召开2026年第一次临时股东会，12月19日股价上涨1.22%
证券之星 · 2025-12-19
亚宝药业（600351）披露拟召开2026年第一次临时股东会，12月19日股价上涨1.22%
亚宝药业(600351.SH)：GLX002获得药物临床试验批准通知书
智通财经 · 2025-12-17
亚宝药业(600351.SH)：GLX002获得药物临床试验批准通知书
每周股票复盘：亚宝药业（600351）出售子公司获益约5900万元
证券之星 · 2025-11-23
每周股票复盘：亚宝药业（600351）出售子公司获益约5900万元
亚宝药业（600351）披露召开2025年第三季度业绩说明会公告，11月21日股价下跌4.05%
证券之星 · 2025-11-21
亚宝药业（600351）披露召开2025年第三季度业绩说明会公告，11月21日股价下跌4.05%
亚宝药业最新公告：拟8719万元出售太原制药62%股权
证券之星 · 2025-11-17
亚宝药业最新公告：拟8719万元出售太原制药62%股权
每周股票复盘：亚宝药业（600351）获特医食品注册证
证券之星 · 2025-11-16
每周股票复盘：亚宝药业（600351）获特医食品注册证
亚宝药业（600351）披露取得特殊医学用途配方食品注册证书，11月12日股价上涨0.29%
证券之星 · 2025-11-12
亚宝药业（600351）披露取得特殊医学用途配方食品注册证书，11月12日股价上涨0.29%
亚宝药业(600351.SH)：“小唯源素®”取得特殊医学用途配方食品注册证书
智通财经网 · 2025-11-12
亚宝药业(600351.SH)：“小唯源素®”取得特殊医学用途配方食品注册证书
每周股票复盘：亚宝药业（600351）回购股份达1.14%，支付金额5215万元
证券之星 · 2025-11-02
每周股票复盘：亚宝药业（600351）回购股份达1.14%，支付金额5215万元
亚宝药业（600351）披露回购股份比例达到1%暨回购进展公告，10月30日股价下跌1.05%
证券之星 · 2025-10-30
亚宝药业（600351）披露回购股份比例达到1%暨回购进展公告，10月30日股价下跌1.05%
股市必读：亚宝药业(600351)股东户数5.37万户，较上期增加9.51%
证券之星 · 2025-10-27
股市必读：亚宝药业(600351)股东户数5.37万户，较上期增加9.51%
亚宝药业（600351）2025年三季报简析：净利润同比下降8.44%，盈利能力上升
证券之星 · 2025-10-26
亚宝药业（600351）2025年三季报简析：净利润同比下降8.44%，盈利能力上升
每周股票复盘：亚宝药业（600351）机构净买入273.2万元，股东户数增9.51%
证券之星 · 2025-10-26
每周股票复盘：亚宝药业（600351）机构净买入273.2万元，股东户数增9.51%
亚宝药业(600351)9月30日股东户数5.37万户，较上期增加9.51%
中金财经 · 2025-10-24
亚宝药业(600351)9月30日股东户数5.37万户，较上期增加9.51%
亚宝药业(600351.SH)发布前三季度业绩，归母净利润2.15亿元，同比下降8.44%
智通财经 · 2025-10-24
亚宝药业(600351.SH)发布前三季度业绩，归母净利润2.15亿元，同比下降8.44%
10月23日亚宝药业现1笔大宗交易 机构净买入273.2万元
证券之星 · 2025-10-23
10月23日亚宝药业现1笔大宗交易 机构净买入273.2万元
每周股票复盘：亚宝药业（600351）亚宝生物获西格列汀二甲双胍缓释片注册证
证券之星 · 2025-10-19
每周股票复盘：亚宝药业（600351）亚宝生物获西格列汀二甲双胍缓释片注册证
加载更多
公司概况
公司名称：
亚宝药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2002-09-26
主营业务：
亚宝药业集团股份有限公司的主营业务是药品及大健康产品的研发、生产和销售。公司的主要产品是儿科类、清热解毒类、心血管系统类、内分泌系统类、神经系统类、精神神经类、抗癫痫类、消化系统类、维生素、矿物质类。
发行价格：
4.80
{"stockData":{"symbol":"600351","market":"SH","secType":"STK","nameCN":"亚宝药业","latestPrice":6.49,"timestamp":1767164401000,"preClose":6.49,"halted":0,"volume":4311326,"delay":0,"changeRate":0,"floatShares":692000000,"shares":692000000,"eps":0.3221,"marketStatus":"已收盘","change":0,"latestTime":"12-31 15:00:00","open":6.48,"high":6.5,"low":6.47,"amount":27969400,"amplitude":0.0046,"askPrice":6.5,"askSize":2185,"bidPrice":6.49,"bidSize":219,"shortable":0,"etf":0,"ttmEps":0.3221,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":6.49,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":7.14,"lowLimit":5.84,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":692000046,"isCdr":false,"pbRate":1.61,"roa":"--","peRate":20.149022,"roe":"7.52%","epsLYR":0.34,"committee":0.150914,"marketValue":4491000000,"turnoverRate":0.0062,"status":2,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-05。","floatMarketCap":4491000000},"requestUrl":"/m/hq/s/600351","defaultTab":"news","newsList":[{"id":"2594220565","title":"亚宝药业（广东横琴）有限公司成立","url":"https://stock-news.laohu8.com/highlight/detail?id=2594220565","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594220565?lang=zh_cn&edition=full","pubTime":"2025-12-28 20:33","pubTimestamp":1766925180,"startTime":"0","endTime":"0","summary":"本报讯 （记者袁传玺）天眼查App显示，近日，亚宝药业（广东横琴）有限公司成立，注册资本1亿元，经营范围包括医学研究和试验发展、生物化工产品技术研发、生物基材料聚合技术研发等。股东信息显示，该公司由亚宝药业（600351）、亚宝药业（澳门）有限公司共同持股。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-12-28/doc-inhekhim0954558.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-28/doc-inhekhim0954558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600351","BK0239","BK0201","BK0028","BK0077","BK0096"],"gpt_icon":0},{"id":"2594242862","title":"每周股票复盘：亚宝药业（600351）拟每10股派现2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594242862","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594242862?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:33","pubTimestamp":1766863990,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，亚宝药业报收于6.57元，较上周的6.65元下跌1.2%。公司公告汇总亚宝药业集团股份有限公司于2025年11月17日召开董事会，审议通过出售控股子公司亚宝药业太原制药有限公司62%股权的议案，交易对价为人民币87,188,740元，受让方为山西同享时代科技有限公司。亚宝药业集团股份有限公司拟以2025年三季度母公司期末未分配利润为基础，向全体股东每10股派发现金红利2元（含税），不送红股，不进行公积金转增股本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0239","BK0077","BK0028","BK0201","600351"],"gpt_icon":0},{"id":"2593408598","title":"亚宝药业（600351）披露拟每10股派发现金红利2元，12月24日股价上涨0.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593408598","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593408598?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:44","pubTimestamp":1766587464,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，亚宝药业报收于6.64元，较前一交易日上涨0.15%，最新总市值为45.95亿元。公告显示，亚宝药业集团股份有限公司拟以2025年三季度母公司期末未分配利润为基础，向全体股东每10股派发现金红利2元（含税），不送红股，不进行公积金转增股本。以当前总股本692,000,046股计算，共计派发现金红利138,400,009.20元（含税）。若股权登记日前总股本变动，将维持每股分配比例不变，相应调整分配总额。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400041403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","BK0239","600351","BK0077","BK0201"],"gpt_icon":0},{"id":"2592748160","title":"亚宝药业（600351）披露拟召开2026年第一次临时股东会，12月19日股价上涨1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592748160","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592748160?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:18","pubTimestamp":1766153926,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，亚宝药业报收于6.65元，较前一交易日上涨1.22%，最新总市值为46.02亿元。近日，亚宝药业集团股份有限公司发布公告称，公司将于2026年1月16日召开2026年第一次临时股东会，会议将采用现场投票与网络投票相结合的方式进行，其中网络投票通过上海证券交易所系统开展。股权登记日为2026年1月9日，现场会议将于当日9点30分在北京市经济技术开发区天华北街11号院2号楼11层会议室召开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351","BK0096","BK0028","BK0077","BK0239","BK0201"],"gpt_icon":0},{"id":"2592962611","title":"亚宝药业(600351.SH)：GLX002获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2592962611","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592962611?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:35","pubTimestamp":1765956945,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚宝药业(600351.SH)发布公告，近日，公司全资子公司北京亚宝生物药业有限公司(简称“亚宝生物”)收到了国家药品监督管理局核准签发的GLX002的《药物临床试验批准通知书》(通知书编号：2025LP03407)。GLX002是基于波生坦分散片的改良型新药，适应症为肺动脉高压(PAH)(WHO第1组)，主要用于改善年龄≥1岁的儿科特发性或先天性PAH患者的肺血管阻力(PVR)，预计可使运动能力得到改善;治疗WHO功能分级Ⅱ级-Ⅳ级的肺动脉高压(PAH)(WHO第1组)的成人患者，以改善运动能力和减少临床恶化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","600351","BK0028","BK0201","BK0077","BK0239"],"gpt_icon":0},{"id":"2585373103","title":"每周股票复盘：亚宝药业（600351）出售子公司获益约5900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585373103","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585373103?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:11","pubTimestamp":1763835069,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，亚宝药业报收于6.4元，较上周的7.04元下跌9.09%。亚宝药业拟将控股子公司亚宝药业太原制药有限公司62%的股权出售给山西同享时代科技有限公司，交易价格为87,188,740元。本次交易预计增加公司2025年度利润总额约5,900万元。截至2025年11月14日，回购期限届满，8,000,000股已办理注销手续，公司股份总数由700,000,046股减少至692,000,046股，注册资本由700,000,046元减少至692,000,046元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351","BK0028","BK0201","BK0077","BK0096","BK0239"],"gpt_icon":0},{"id":"2585514952","title":"亚宝药业（600351）披露召开2025年第三季度业绩说明会公告，11月21日股价下跌4.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585514952","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585514952?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:25","pubTimestamp":1763735116,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，亚宝药业报收于6.4元，较前一交易日下跌4.05%，最新总市值为44.29亿元。该股当日开盘6.63元，最高6.69元，最低6.4元，成交额达1.17亿元，换手率为2.6%。公司近日发布公告称，亚宝药业集团股份有限公司将于2025年12月01日14:00-15:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司经营成果及财务状况。投资者可于2025年11月24日至11月28日16:00前通过上证路演中心或公司邮箱wangyu@yabaoyaoye.com提问，说明会后可通过该平台查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351","BK0201","BK0077","BK0028","BK0239","BK0096"],"gpt_icon":0},{"id":"2584641288","title":"亚宝药业最新公告：拟8719万元出售太原制药62%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2584641288","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584641288?lang=zh_cn&edition=full","pubTime":"2025-11-17 18:20","pubTimestamp":1763374843,"startTime":"0","endTime":"0","summary":"亚宝药业(600351.SH)公告称，公司拟将控股子公司太原制药62%的股权出售给同享科技，交易价格为8718.87万元。交易完成后，同享科技将持有太原制药95%的股权，公司持有5%，太原制药将不再纳入合并报表。本次交易不构成关联交易或重大资产重组，无需提交股东会审议。交易对方具备履约能力，但存在不能按协议及时支付股权转让对价的风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700025810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","600351","BK0077","BK0028","BK0201","BK1574","01477","BK0096"],"gpt_icon":0},{"id":"2583955654","title":"每周股票复盘：亚宝药业（600351）获特医食品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2583955654","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583955654?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:45","pubTimestamp":1763239512,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，亚宝药业报收于7.04元，较上周的6.84元上涨2.92%。本周，亚宝药业11月14日盘中最高价报7.09元。亚宝药业当前最新总市值49.28亿元，在中药板块市值排名45/67，在两市A股市值排名3418/5165。本周关注点公司公告汇总：亚宝药业取得小唯源素特殊医学用途配方食品注册证书。注册号为国食注字TY20250052，有效期至2030年10月26日。公司已累计投入研发费用约407.42万元。该产品注册获批有助于提升公司竞争力，但短期内对公司业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351","BK0239","BK0096","BK0028","BK0077","BK0201"],"gpt_icon":0},{"id":"2582541370","title":"亚宝药业（600351）披露取得特殊医学用途配方食品注册证书，11月12日股价上涨0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582541370","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582541370?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:43","pubTimestamp":1762958598,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，亚宝药业报收于6.98元，较前一交易日上涨0.29%，最新总市值为48.86亿元。公司近日发布公告称，亚宝药业集团股份有限公司近日收到国家市场监督管理总局核准签发的《特殊医学用途配方食品注册证书》，产品名为小唯源素，属于特殊医学用途全营养配方食品，适用于1～10岁进食受限、消化吸收障碍、代谢紊乱等需要补充营养的人群。注册号为国食注字TY20250052，有效期至2030年10月26日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0201","BK0077","600351","BK0096","BK0239"],"gpt_icon":0},{"id":"2582328611","title":"亚宝药业(600351.SH)：“小唯源素®”取得特殊医学用途配方食品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582328611","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582328611?lang=zh_cn&edition=full","pubTime":"2025-11-12 15:46","pubTimestamp":1762933564,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚宝药业(600351.SH)发布公告，近日，公司收到了国家市场监督管理总局核准签发的《特殊医学用途配方食品注册证书》，该商品名称：“小唯源素®”。小唯源素®特殊医学用途全营养配方食品是公司研发的一款适用于1～10岁进食受限、消化吸收障碍、代谢紊乱等需要补充营养的人群的全营养配方食品，可作为单一营养来源满足目标人群营养需求。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚宝药业(600351.SH)：“小唯源素®”取得特殊医学用途配方食品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600351","BK0239","BK0201","BK0028","BK0077","BK0096"],"gpt_icon":0},{"id":"2580440814","title":"每周股票复盘：亚宝药业（600351）回购股份达1.14%，支付金额5215万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580440814","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580440814?lang=zh_cn&edition=full","pubTime":"2025-11-02 09:01","pubTimestamp":1762045281,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，亚宝药业报收于6.72元，较上周的6.74元下跌0.3%。本周，亚宝药业10月27日盘中最高价报6.77元。10月30日盘中最低价报6.61元。亚宝药业当前最新总市值47.04亿元，在中药板块市值排名45/67，在两市A股市值排名3477/5163。截至2025年10月30日，公司已累计回购股份8,000,000股，占总股本的1.14%，已支付总金额52,151,912.00元，回购最高价6.65元/股，最低价6.30元/股。回购进展符合相关法规及方案要求。公司将继续履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351","BK0239","BK0096","BK0028","BK0077","BK0201"],"gpt_icon":0},{"id":"2579996125","title":"亚宝药业（600351）披露回购股份比例达到1%暨回购进展公告，10月30日股价下跌1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579996125","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579996125?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:27","pubTimestamp":1761834465,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，亚宝药业报收于6.62元，较前一交易日下跌1.05%，最新总市值为46.34亿元。该股当日开盘6.69元，最高6.71元，最低6.61元，成交额达8246.87万元，换手率为1.77%。公司近日发布公告称，自2025年5月16日召开2024年年度股东大会审议通过以集中竞价交易方式回购股份方案以来，截至2025年10月30日，已累计回购股份8,000,000股，占公司总股本的1.14%。公司表示，回购进展符合相关法规及回购方案要求，并将持续履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000045441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","600351","BK0028","BK0201","BK0077","BK0239"],"gpt_icon":0},{"id":"2578654727","title":"股市必读：亚宝药业(600351)股东户数5.37万户，较上期增加9.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578654727","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578654727?lang=zh_cn&edition=full","pubTime":"2025-10-27 03:34","pubTimestamp":1761507251,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，亚宝药业报收于6.74元，下跌1.32%，换手率1.76%，成交量12.3万手，成交额8334.84万元。交易信息汇总资金流向10月24日主力资金净流出1032.86万元，占总成交额12.39%；游资资金净流入123.39万元，占总成交额1.48%；散户资金净流入909.47万元，占总成交额10.91%。股本股东变化股东户数变动截至2025年9月30日，亚宝药业股东户数为5.37万户，较6月30日增加4662.0户，增幅为9.51%。户均持股数量由上期的1.43万股减少至1.3万股，户均持股市值为8.53万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700000904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351","BK0096","BK0077","BK0239","BK0028","BK0201"],"gpt_icon":0},{"id":"2578833006","title":"亚宝药业（600351）2025年三季报简析：净利润同比下降8.44%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2578833006","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578833006?lang=zh_cn&edition=full","pubTime":"2025-10-26 06:01","pubTimestamp":1761429685,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亚宝药业发布2025年三季报。截至本报告期末，公司营业总收入17.09亿元，同比下降19.46%，归母净利润2.15亿元，同比下降8.44%。按单季度数据看，第三季度营业总收入5.69亿元，同比下降16.01%，第三季度归母净利润4069.71万元，同比下降26.22%。本报告期亚宝药业盈利能力上升，毛利率同比增幅0.74%，净利率同比增幅7.87%。去年的净利率为8.34%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600351"],"gpt_icon":0},{"id":"2578502844","title":"每周股票复盘：亚宝药业（600351）机构净买入273.2万元，股东户数增9.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578502844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578502844?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:57","pubTimestamp":1761418629,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，亚宝药业报收于6.74元，较上周的6.75元下跌0.15%。本周，亚宝药业10月22日盘中最高价报6.91元。10月20日盘中最低价报6.68元。亚宝药业当前最新总市值47.18亿元，在中药板块市值排名44/67，在两市A股市值排名3438/5160。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0028","BK0096","600351","BK0239","BK0077"],"gpt_icon":0},{"id":"2577759901","title":"亚宝药业(600351)9月30日股东户数5.37万户，较上期增加9.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577759901","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577759901?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:26","pubTimestamp":1761298019,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亚宝药业披露，截至2025年9月30日公司股东户数为5.37万户，较6月30日增加4662.0户，增幅为9.51%。在中药行业个股中，亚宝药业股东户数高于行业平均水平，截至9月30日，中药行业平均股东户数为5.32万户。从股价来看，2025年6月30日至2025年9月30日，亚宝药业区间涨幅为7.74%，在此期间股东户数增加4662.0户，增幅为9.51%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/24/20251024185587.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/24/20251024185587.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251024/31734525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0077","600351","BK0239","BK0028","BK0201","BK0096"],"gpt_icon":0},{"id":"2577598787","title":"亚宝药业(600351.SH)发布前三季度业绩，归母净利润2.15亿元，同比下降8.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577598787","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577598787?lang=zh_cn&edition=full","pubTime":"2025-10-24 16:04","pubTimestamp":1761293075,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚宝药业(600351.SH)披露2025年第三季度报告，公司前三季度实现营收17.09亿元，同比下降19.46%;归母净利润2.15亿元，同比下降8.44%;扣非净利润1.97亿元，同比下降9.03%;基本每股收益0.3066元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"亚宝药业(600351.SH)发布前三季度业绩，归母净利润2.15亿元，同比下降8.44%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600351"],"gpt_icon":0},{"id":"2577237462","title":"10月23日亚宝药业现1笔大宗交易 机构净买入273.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577237462","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577237462?lang=zh_cn&edition=full","pubTime":"2025-10-23 17:20","pubTimestamp":1761211248,"startTime":"0","endTime":"0","summary":"证券之星消息，10月23日亚宝药业发生大宗交易，交易数据如下：大宗交易成交价格6.83元，成交40万股，成交金额273.2万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司太原南中环街证券营业部。近三个月该股共发生1笔大宗交易，合计成交4000.0手。该股近期无解禁股上市。截至2025年10月23日收盘，亚宝药业报收于6.83元，下跌0.58%，换手率1.74%，成交量12.2万手，成交额8304.24万元。该股最近90天内共有1家机构给出评级，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300026872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600351","BK0201","BK0096","BK0077"],"gpt_icon":0},{"id":"2576046583","title":"每周股票复盘：亚宝药业（600351）亚宝生物获西格列汀二甲双胍缓释片注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2576046583","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576046583?lang=zh_cn&edition=full","pubTime":"2025-10-19 02:40","pubTimestamp":1760812821,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，亚宝药业报收于6.75元，较上周的6.68元上涨1.05%。本周关注点公司公告汇总：全资子公司北京亚宝生物取得西格列汀二甲双胍缓释片药品注册证书。该药品适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。截至目前，国内共有12家企业取得该品种注册批文。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","600351","BK0096","BK0201","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767316269130,"stockEarnings":[{"period":"1week","weight":-0.0226},{"period":"1month","weight":-0.0211},{"period":"3month","weight":-0.0076},{"period":"6month","weight":0.0367},{"period":"1year","weight":0.1186},{"period":"ytd","weight":0.1186}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"亚宝药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"53669人(较上一季度增加9.51%)","perCapita":"12893股","listingDate":"2002-09-26","address":"山西省运城市芮城县富民路43号","registeredCapital":"69200万元","survey":" 亚宝药业集团股份有限公司的主营业务是药品及大健康产品的研发、生产和销售。公司的主要产品是儿科类、清热解毒类、心血管系统类、内分泌系统类、神经系统类、精神神经类、抗癫痫类、消化系统类、维生素、矿物质类。","listedPrice":4.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚宝药业(600351)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚宝药业(600351)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚宝药业,600351,亚宝药业股票,亚宝药业股票老虎,亚宝药业股票老虎国际,亚宝药业行情,亚宝药业股票行情,亚宝药业股价,亚宝药业股市,亚宝药业股票价格,亚宝药业股票交易,亚宝药业股票购买,亚宝药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚宝药业(600351)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚宝药业(600351)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}